PHP-303 is under clinical development by Peak Bio and currently in Phase I for Alpha-1 Antitrypsin Deficiency (A1AD). According to GlobalData, Phase I drugs for Alpha-1 Antitrypsin Deficiency (A1AD) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PHP-303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PHP-303 overview

PHP-303 (BAY-858501) is under development for the treatment of alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome associated with COVID-19. It is administered through oral route as a film coated tablet. The drug candidate acts by targeting neutrophil elastase (NEI). It was also under development for the treatment of acute lung injury, non-alcoholic steatohepatitis (NASH) and non-cystic fibrosis bronchiectasis.

Peak Bio overview

Peak Bio is a biopharmaceutical company that engaged in developing and commercializing therapeutics for the treatment of oncology and inflammatory diseases. The company is headquartered in Palo Alto, California, the US.

For a complete picture of PHP-303’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.